

High-intensity interval training versus moderate-intensity continuous training for cardiometabolic health in adults with metabolic syndrome

Submission date 19/07/2025	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 23/07/2025	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 23/07/2025	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

This study aims to compare the effects of two types of exercise, High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT), on the health of middle-aged adults with metabolic syndrome. Metabolic syndrome includes conditions like high blood pressure, high blood sugar, abnormal cholesterol levels, and increased waist circumference, which raise the risk of heart disease and diabetes. The goal is to identify which type of exercise is more effective in improving health outcomes for people at risk of chronic diseases.

Who can participate?

Adults aged 40 to 60 years who have been diagnosed with metabolic syndrome

What does the study involve?

Participants will be randomly assigned to one of three groups: HIIT group, MICT group, or a control group that does not receive any specific exercise intervention. The exercise programs will last 12 weeks, with 3 sessions per week. The HIIT group will perform short bursts of intense exercise followed by rest periods, while the MICT group will perform moderate, steady-state exercises such as brisk walking or cycling. The researchers will measure various health markers before, during, and after the 12 weeks, including blood sugar, cholesterol, liver function, body weight, inflammation, and heart rate recovery.

What are the possible benefits and risks of participating?

All participants will receive professional supervision, and their safety will be closely monitored throughout the study. The findings may help develop better exercise programs for people with metabolic health issues.

Participants may experience temporary discomfort such as muscle soreness, fatigue, increased heart rate, or mild dizziness during training. All sessions are supervised by trained professionals. Emergency medical equipment (e.g., AED) is available at all training sites, and participants may withdraw from the study at any time without penalty. These risks are minimal and well-managed.

Where is the study run from?

Henan University, Kyungil University in South Korea, and Wangkui County Health Bureau, China

When is the study starting and how long is it expected to run for?

September 2024 to May 2025

Who is funding the study?

Investigator initiated and funded

Who is the main contact?

Dr Yongheng Zhao, zyh1996@ldy.edu.rs, zyh19960705@gmail.com

Contact information

Type(s)

Public, Scientific, Principal Investigator

Contact name

Dr Yongheng Zhao

Contact details

Wangkui County, Suihua City, Heilongjiang Province

Kaifeng

China

475001

+86 13029925007

zyh1996@ldy.edu.rs

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

A 12-week randomised controlled trial comparing the effects of HIIT and MICT on glycemic control, lipid metabolism, liver enzymes, and cardiovascular function in adults with metabolic syndrome

Acronym

HIIT-MICT MetS Trial

Study objectives

To compare the effects of high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) on glycemic control, lipid metabolism, hepatic function, systemic inflammation, and heart rate recovery in middle-aged adults with metabolic syndrome. A secondary objective is to explore potential sex-specific differences in intervention responsiveness.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 01/11/2024, Wangkui County Health and Wellness Bureau (No.18 Zhongyang Avenue, Wangkui County, Suihua City, Heilongjiang Province, 152100, China; +86 13298751511; wyj1973@ldy.edu.rs), ref: WLJ-2024-032

Study design

12-week single-center three-arm parallel-group, randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised parallel trial

Study setting(s)

Community, Fitness/sport facility, Hospital, University/medical school/dental school

Study type(s)

Prevention, Treatment, Efficacy

Participant information sheet

See study outputs table

Health condition(s) or problem(s) studied

Metabolic syndrome, including components such as hypertension, dyslipidemia (elevated triglycerides, low HDL-C), impaired glucose regulation (elevated fasting glucose or HbA1c), and abdominal obesity. The study population consists of middle-aged adults at high risk of cardiometabolic disorders, aiming to evaluate the efficacy of exercise interventions for cardiometabolic risk reduction and disease prevention.

Interventions

This study is a 12-week, single-center, three-arm, parallel-group, randomized controlled trial (RCT) designed to compare the effects of high-intensity interval training (HIIT) and moderate-

intensity continuous training (MICT) on multiple cardiometabolic health outcomes in middle-aged adults with metabolic syndrome.

A total of 90 participants (aged 45–65) with at least one component of metabolic syndrome were recruited from Wangkui County, Heilongjiang Province, China. After screening, eligible participants were stratified by sex and randomly assigned (1:1:1) to one of three groups: HIIT, MICT, or non-exercise control (CON). Randomization was performed using a computer-generated block randomization sequence (block size = 6) by an independent statistician. Allocation was concealed using sequentially numbered, opaque, sealed envelopes. Due to the nature of the intervention, participant blinding was not feasible, but outcome assessors and data analysts were blinded to group allocation.

The two structured exercise interventions and one non-exercise control group are as follows:

1. The HIIT (High-Intensity Interval Training) group performed a 12-week intervention, 3 times per week, using a 4×4 protocol adapted from Helgerud et al. Each session consisted of a 5-minute warm-up at 50% HRmax, followed by 4 intervals of 4 minutes at 85–95% HRmax, interspersed with 4 minutes of active recovery at 50–60% HRmax, and concluded with a cooldown. Sessions were conducted on treadmills or cycling ergometers, supervised by certified trainers.
2. The MICT (Moderate-Intensity Continuous Training) group completed a 12-week aerobic training program, 5 times per week, at 60–70% HRmax. Each session lasted approximately 45 minutes and involved continuous brisk walking, jogging, or cycling. Heart rate monitors (Polar H10) were used to ensure intensity adherence.
3. The Control group received no structured exercise but maintained their usual lifestyle. Participants attended health education sessions to control for nonspecific effects.

Primary outcomes were changes in fasting blood glucose (FBG) and glycated hemoglobin (HbA1c). Secondary outcomes included lipid profile (TG, HDL-C, LDL-C), BMI, alanine aminotransferase (ALT), uric acid (UA), high-sensitivity C-reactive protein (hs-CRP), and heart rate recovery (HRR), assessed at baseline, mid-intervention (week 6), and post-intervention (week 12).

The study adhered to the ethical principles of the Declaration of Helsinki and was approved by the Health Commission of Wangkui County (Approval No.: WYHE-2024-01). All participants provided written informed consent before enrollment.

All exercise sessions took place at fitness facilities or health centers in Wangkui County, with medical supervision and safety monitoring. Intervention fidelity was tracked through electronic attendance logs and training records.

Intervention Type

Behavioural

Primary outcome measure

Change in fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) levels were measured using standardized venous blood assays in a central laboratory from at baseline (T1), mid-intervention (T2, week 6), and post-intervention (T3, week 12)

Secondary outcome measures

The following secondary outcome measures were conducted using standardized protocols under blinded laboratory conditions. Intermediate measurements were taken at week 6 to observe dynamic responses to intervention:

1. Change in triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels measured using fasting venous blood samples in a central laboratory from baseline to week 12
2. Change in body mass index (BMI), calculated from measured weight and height, assessed at baseline, week 6, and week 12
3. Change in serum alanine aminotransferase (ALT) levels, used as a marker of liver function, measured using standardized procedures from baseline to week 12
4. Change in serum uric acid (UA) levels measured using biochemical assays from baseline to week 12
5. Change in high-sensitivity C-reactive protein (hs-CRP) levels, as an index of systemic inflammation, measured using standardized procedures from baseline to week 12
6. Change in heart rate recovery (HRR), defined as the drop in heart rate within 1 minute after exercise cessation, and measured using Polar H10 monitors at week 0, 6, and 12

Overall study start date

01/09/2024

Completion date

31/05/2025

Eligibility

Key inclusion criteria

1. Adults aged 40 to 60 years
2. Diagnosed with metabolic syndrome based on at least three of the following criteria (as per IDF or Chinese guidelines):
 - 2.1. Elevated waist circumference
 - 2.2. Elevated triglycerides (≥ 150 mg/dL)
 - 2.3. Reduced HDL cholesterol (< 40 mg/dL for men, < 50 mg/dL for women)
 - 2.4. Elevated blood pressure (SBP ≥ 130 mmHg or DBP ≥ 85 mmHg)
 - 2.5. Elevated fasting blood glucose (≥ 100 mg/dL)
3. Able and willing to provide written informed consent
4. Physically capable of participating in supervised moderate-to-high intensity exercise programs
5. No change in medication for at least 3 months prior to enrolment

Participant type(s)

Patient

Age group

Adult

Lower age limit

40 Years

Upper age limit

60 Years

Sex

Both

Target number of participants

120

Total final enrolment

78

Key exclusion criteria

1. Diagnosed with severe cardiovascular disease (e.g., unstable angina, recent myocardial infarction within 6 months)
2. Diagnosed with severe pulmonary disease or respiratory insufficiency
3. Diagnosed with advanced liver or renal dysfunction
4. History of stroke or other neurological disorders affecting motor ability
5. Musculoskeletal disorders or injuries preventing safe exercise participation
6. Currently receiving chemotherapy, radiotherapy, or immunosuppressive treatment
7. Diagnosed psychiatric illness or cognitive impairment that limits informed consent or compliance
8. Participation in any other clinical trial within the past 3 months
9. Pregnancy or planning to become pregnant during the study period
10. Refusal or inability to provide written informed consent

Date of first enrolment

01/11/2024

Date of final enrolment

30/11/2024

Locations

Countries of recruitment

China

Study participating centre

Wangkui County

Suihua City, Heilongjiang province

Kaifeng

China

475001

Sponsor information

Organisation

Wangkui County Health Commission

Sponsor details

No. 98 Xinhua Street, Wangkui County
Suihua
China
475001
+86 13298751511
819960705@qq.com

Sponsor type

Government

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal

Intention to publish date

01/11/2025

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the results publication. IPD will not be shared due to privacy and ethical concerns. Aggregated results only will be made available through publications.

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet			23/07/2025	No	Yes
Protocol file			23/07/2025	No	No